Benitec Biopharma Inc. (NASDAQ: BNTC) is a Healthcare company (Biotechnology) with a market capitalization of $284M. The Maz Rating grades it against the other companies in its sector.
Benitec Biopharma Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $8.15, Benitec Biopharma Inc. trades at 2.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -27.6%, return on invested capital of -32.8% and a free cash flow yield of -6.1%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 19.62. Over the past 52 weeks the share price ranged from $7.88 to $14.39, with a beta of 0.25.
Benitec Biopharma Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 7 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Benitec Biopharma Inc. (BNTC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.13% / 30% · (Cash+Inv) / Mkt Cap (36m) 35.8% / 30% · Interest income / Revenue 157600000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.13% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 35.8% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 157600000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.13% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 35.8% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 157600000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.14% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 98.7% / 33.33% · Receivables / Avg Assets (4Q) 0.02% / 33.33% · Interest income / Revenue 157600000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.36% / 33.33% · (Cash+ST Inv) / Total Assets 98.5% / 33.33% · (Cash+Recv) / Total Assets 98.5% / 33.33% · Interest income / Revenue 157600000.0% / 5% | Fail |
No. As of September 2026, Benitec Biopharma Inc. (BNTC) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Benitec Biopharma Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 157600000.0% of each dividend: Benitec Biopharma Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q1 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.